SRSF2 and acute myeloid leukemia: In preclinical xenograft models for acute myeloid leukemia (AML); however, the spliceosome inhibitor E7107 preferentially led to intron retention in Srsf2-mutated samples and reductions in leukemia burden, suggesting a possible therapeutic window for these agents38.